vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $19.07 and traded as low as $15.72. vTv Therapeutics shares last traded at $15.67, with a volume of 720 shares.

Analysts Set New Price Targets

Several research firms recently issued reports on VTVT. Wall Street Zen began coverage on shares of vTv Therapeutics in a research report on Wednesday, April 16th. They issued a “sell” rating on the stock. HC Wainwright initiated coverage on shares of vTv Therapeutics in a research note on Wednesday, April 9th. They set a “buy” rating and a $36.00 price target on the stock.

vTv Therapeutics Price Performance

The stock has a 50-day simple moving average of $19.07 and a 200-day simple moving average of $17.27. The stock has a market cap of $49.97 million, a PE ratio of -5.20 and a beta of 0.59.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.04).

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds have recently made changes to their positions in VTVT. Geode Capital Management LLC boosted its position in vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the period. Connective Capital Management LLC purchased a new stake in shares of vTv Therapeutics in the first quarter worth about $162,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at about $25,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.